Korean South West Oncology Group Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2010
NCT01234051
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Korean Southwest Oncology Group | Korean South West Oncology Group

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Biliary Tract Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Large Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 6